NMC Health Plc Statement re. share price movement (4301I)
08 August 2019 - 8:46PM
UK Regulatory
TIDMNMC
RNS Number : 4301I
NMC Health Plc
08 August 2019
8 August 2019
NMC Health plc
(the "Company" or "NMC")
Statement re. share price movement
NMC Health plc (LSE: NMC), the leading private healthcare
operator in the Gulf Cooperation Council (GCC) with international
services across 19 countries, notes the recent share price weakness
and confirms that it expects to report that, after a good
performance in the first half of 2019, trading in the business
remains in line with management expectations on all key metrics
including revenue, EBITDA, net income, leverage, cash flow
conversion and working capital. Full year guidance remains as
previously stated.
In accordance with accounting requirements, the Company will be
reporting its interim results on a post-IFRS 16 basis but intends
to also provide pre-IFRS 16 comparators for the purposes of those
sell-side research analysts that continue to forecast the Company's
performance on such basis.
The Company will be able to comment in further detail and will
be reporting its interim results on 22 August 2019 in line with the
statement released on Monday 5 August 2019.
Contacts
NMC
Asjad Yahya, Investor Relations +971 (0)56 219 0975
Media
FTI Consulting, London
Brett Pollard / Victoria Foster Mitchell/
Mary Whittow +44 (0)20 3727 1000
FTI Consulting, Gulf
Shane Dolan +971 (0)4 437 2100
About NMC Health
NMC is the leading private healthcare operator in the GCC with
an international network of healthcare facilities across 19
countries. NMC ranks as one of the top two in-vitro fertilisation
("IVF") operators globally. The Group is recognised as a leading
provider of long-term medical care in the UAE through its
subsidiary ProVita. Pursing a selective international expansion
program since 2016, the company now has total capacity of 3,109
beds across its network with 48% of this capacity in the Kingdom of
Saudi Arabia (KSA), where the company has introduced long-term and
multi-specialty care services. Moreover, the recent formation of a
joint venture with GOSI/Hassana Investment Company provides a solid
platform for continued growth in the GCC region's largest
healthcare market. NMC treated over 7.5m patients in 2018. The
Group is also a leading UAE supplier of products and consumables
across several key market segments, with the major contribution
coming from healthcare related products. The Group reported
revenues of US$2.1 billion for the year ended 31 December 2018.
In April 2012 NMC was listed on the Premium Segment of the
London Stock Exchange. NMC is a constituent of the FTSE 100
Index.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
SPMUWSRRKVAWRAR
(END) Dow Jones Newswires
August 08, 2019 06:46 ET (10:46 GMT)
Nmc Health (LSE:NMC)
Historical Stock Chart
From Apr 2024 to May 2024
Nmc Health (LSE:NMC)
Historical Stock Chart
From May 2023 to May 2024